Compile Data Set for Download or QSAR
Report error Found 170 Enz. Inhib. hit(s) with all data for entry = 8776
TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461068BDBM50461068(CHEMBL4228069 | US10457637, Compound 24)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419256BDBM419256(N-(2,4-dimethylphenyl)-N- isobutyl-3-(S- methylsul...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419256BDBM419256(N-(2,4-dimethylphenyl)-N- isobutyl-3-(S- methylsul...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419252BDBM419252(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419157BDBM419157(N-(4-ethylphenyl)-3- hydroxymethyl-N-isobutyl- 4-(...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419252BDBM419252(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419155BDBM419155(N-(4-ethylphenyl)-N- isobutyl-3-methanesulfinyl- 4...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461065BDBM50461065(CHEMBL4225020 | US10457637, Compound 18)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461065BDBM50461065(CHEMBL4225020 | US10457637, Compound 18)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419154BDBM419154(N-(4-ethylphenyl)-N- isobutyl-3-methanesulfinyl- 4...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419154BDBM419154(N-(4-ethylphenyl)-N- isobutyl-3-methanesulfinyl- 4...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419169BDBM419169(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonom...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419218BDBM419218(4-((((1R,5S,6S)-3- oxabicyclo[3.1.0]hexan-6- yl)me...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419167BDBM419167(4-(((1R,5S,6R)-3- oxabicyclo[3.1.0]hexan-6- yl)met...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419218BDBM419218(4-((((1R,5S,6S)-3- oxabicyclo[3.1.0]hexan-6- yl)me...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419162BDBM419162(N-(4-ethylphenyl)-4-((4- fluorotetrahydro-2H-pyran...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419214BDBM419214(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419162BDBM419162(N-(4-ethylphenyl)-4-((4- fluorotetrahydro-2H-pyran...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419214BDBM419214(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419163BDBM419163(4-((3- oxabicyclo[3.1.0]hexan-6- yl)methoxy)-N-(4-...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461075BDBM50461075(CHEMBL4225072 | US10457637, Compound 55)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419234BDBM419234(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419139BDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419139BDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419139BDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461066BDBM50461066(CHEMBL4228566 | US10457637, Compound 53)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461066BDBM50461066(CHEMBL4228566 | US10457637, Compound 53)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419233BDBM419233(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461075BDBM50461075(CHEMBL4225072 | US10457637, Compound 55)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461074BDBM50461074(CHEMBL4227729 | US10457637, Compound 52)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461074BDBM50461074(CHEMBL4227729 | US10457637, Compound 52)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419225BDBM419225(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419225BDBM419225(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461069BDBM50461069(CHEMBL4228522 | US10457637, Compound 66)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419192BDBM419192(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461076BDBM50461076(CHEMBL4227214 | US10457637, Compound 124)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461076BDBM50461076(CHEMBL4227214 | US10457637, Compound 124)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461069BDBM50461069(CHEMBL4228522 | US10457637, Compound 66)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461083BDBM50461083(CHEMBL4225889 | US10457637, Compound 62)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419242BDBM419242(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419192BDBM419192(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419242BDBM419242(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419139BDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419189BDBM419189(N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461063BDBM50461063(CHEMBL4226803 | US10457637, Compound 8)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419189BDBM419189(N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461063BDBM50461063(CHEMBL4226803 | US10457637, Compound 8)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461083BDBM50461083(CHEMBL4225889 | US10457637, Compound 62)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 50461068BDBM50461068(CHEMBL4228069 | US10457637, Compound 24)
Affinity DataIC50: 550nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandChemical structure of BindingDB Monomer ID 419160BDBM419160(N-(4-ethylphenyl)-N- isobutyl-3-methylsulfanyl-4- ...)
Affinity DataIC50: 550nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
US Patent

Displayed 1 to 50 (of 170 total ) | Next | Last >>
Jump to: